The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02612922




Registration number
NCT02612922
Ethics application status
Date submitted
20/11/2015
Date registered
24/11/2015
Date last updated
4/04/2018

Titles & IDs
Public title
Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Scientific title
A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Secondary ID [1] 0 0
RM08-3003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Influenza 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Nitazoxanide
Treatment: Drugs - Placebo

Active Comparator: Nitazoxanide - Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days

Placebo Comparator: Placebo - Two Placebo tablets orally twice daily (b.i.d.) for 5 days


Treatment: Drugs: Nitazoxanide
Nitazoxanide 600 mg administered orally twice daily for five days

Treatment: Drugs: Placebo
Placebo administered orally twice daily for five days

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to alleviation of all clinical symptoms of influenza
Timepoint [1] 0 0
Up to 28 days
Secondary outcome [1] 0 0
Time to alleviation of each individual symptom of influenza
Timepoint [1] 0 0
Up to 28 days

Eligibility
Key inclusion criteria
1. Age 12 to 65 years

2. Presence of clinical signs and/or symptoms consistent with an acute illness compatible
with influenza infection (each of the following is required):

- oral temperature of =100.4°F or =38°C (obtained in office or self-measured within
12 hours prior to screening - if self-measured, subject must also have taken an
antipyretic within 4 hours prior to screening) AND

- at least one of the following respiratory symptoms (cough, sore throat, nasal
obstruction), AND

- one of the following constitutional symptoms (fatigue, headache, myalgia,
feverishness).

3. Confirmation of influenza A or B infection in the local community by one of the
following means:

- the institution's local laboratory,

- the local public health system,

- the national public health system, or

- a laboratory of a recognized national or multinational influenza surveillance
scheme.

4. Onset of illness no more than 40 hours before enrollment in the trial.

Note: Time of onset of illness is defined as either the earlier of:

- the time when the temperature was first measured as elevated, OR

- the time when the subject experienced the presence of at least one respiratory
symptom AND the presence of at least one constitutional symptom.

5. Willing and able to provide written informed consent (including assent by legal
guardian if under 18 years of age) and comply with the requirements of the protocol,
including completion of the patient diary.
Minimum age
12 Years
Maximum age
65 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Severity of illness requiring or anticipated to require in-hospital care or subject
defined as being at high risk of complications from influenza infection according to
the Infectious Diseases Society of America (IDSA) guidelines for seasonal influenza in
adults and children (Committee of Infectious Diseases (CID) 2009:48) or current
Centers for Disease Control and Prevention (CDC) criteria. Current criteria for
persons 12-65 years of age who are at risk of influenza complications include (list to
be reviewed and updated as required prior to initiation of the study and at least
monthly during the study):

- Persons with asthma or other chronic pulmonary diseases, such as cystic fibrosis
in children or chronic obstructive pulmonary disease in adults.

- Persons with hemodynamically significant cardiac disease.

- Persons who have immunosuppressive disorders or who are receiving
immunosuppressive therapy.

- Human Immunodeficiency Virus (HIV) infected persons.

- Persons with sickle cell anemia or other hemoglobinopathies.

- Persons with diseases requiring long-term aspirin therapy, such as rheumatoid
arthritis or Kawasaki disease.

- Persons with chronic renal dysfunction.

- Persons with liver disorders.

- Persons with active cancer.

- Persons with chronic metabolic disease, such as diabetes mellitus, inherited
metabolic disorders and mitochondrial disorders.

- Persons with neuromuscular disorders, seizure disorders or cognitive dysfunction
that may compromise the handling of respiratory secretions.

- Residents of any age of nursing homes or other long-term care institutions.

- Persons who are morbidly obese (Body Mass Index =40).

- American Indians.

- Alaskan natives.

2. Females of childbearing potential who are either pregnant, breast-feeding or are
sexually active without the use of birth control. Female subjects of child-bearing
potential that are sexually active must have a negative baseline pregnancy test and
must agree to continue an acceptable method of birth control for the duration of the
study and for 1 month post-treatment. A double barrier method, oral birth control
pills administered for at least 2 monthly cycles prior to study drug administration,
an intrauterine device (IUD), or medroxyprogesterone acetate administered
intramuscularly for a minimum of one month prior to study drug administration are
acceptable methods of birth control for inclusion into the study. Female subjects are
considered of childbearing potential unless they are postmenopausal (absence of
menstrual bleeding for 1 year - or 6 months if laboratory confirmation of hormonal
status), or have had a hysterectomy, bilateral tubular ligation or bilateral
ovariectomy.

3. Vaccination for seasonal influenza on or after August 1, 2015.

4. Receipt of any dose of nitazoxanide, oseltamivir, zanamivir, peramivir, amantadine or
rimantadine within 30 days prior to screening.

5. Prior treatment with any investigational drug therapy within 30 days prior to
screening.

6. Subjects with active respiratory allergies or subjects expected to require
anti-allergy medications during the study period for respiratory allergies.

7. Known sensitivity to nitazoxanide or any of the excipients comprising the nitazoxanide
tablets.

8. Subjects unable to take oral medications.

9. Subject has chronic kidney or liver disease (including Hepatitis A, B or C) or known
impaired hepatic and/or renal function.

10. Presence of any other pre-existing chronic infection that is undergoing or requiring
medical therapy.

11. Presence of any pre-existing illness that, in the opinion of the Investigator, would
place the subject at an unreasonably increased risk through participation in this
study.

12. Subjects who, in the judgment of the Investigator, will be unlikely to comply with the
requirements of this protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Influence Study Site - Brookvale
Recruitment hospital [2] 0 0
Influence Study Site - Castle Hill
Recruitment hospital [3] 0 0
Influence Study Site - Mosman
Recruitment hospital [4] 0 0
Influence Study Site - Browns Plains
Recruitment hospital [5] 0 0
Influence Study Site - Springfield
Recruitment hospital [6] 0 0
Influence Study Site - Berwick
Recruitment hospital [7] 0 0
Influence Study Site - Lynbrook
Recruitment hospital [8] 0 0
Influence Study Site - Rosebud
Recruitment hospital [9] 0 0
Influence Study Site - Tarneit
Recruitment postcode(s) [1] 0 0
2100 - Brookvale
Recruitment postcode(s) [2] 0 0
2154 - Castle Hill
Recruitment postcode(s) [3] 0 0
2088 - Mosman
Recruitment postcode(s) [4] 0 0
4118 - Browns Plains
Recruitment postcode(s) [5] 0 0
4300 - Springfield
Recruitment postcode(s) [6] 0 0
3806 - Berwick
Recruitment postcode(s) [7] 0 0
3957 - Lynbrook
Recruitment postcode(s) [8] 0 0
3939 - Rosebud
Recruitment postcode(s) [9] 0 0
3029 - Tarneit
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Pennsylvania
Country [6] 0 0
United States of America
State/province [6] 0 0
South Dakota
Country [7] 0 0
United States of America
State/province [7] 0 0
Tennessee
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
Puerto Rico
State/province [9] 0 0
San Juan

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Romark Laboratories L.C.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of acute
uncomplicated influenza.
Trial website
https://clinicaltrials.gov/show/NCT02612922
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jean-Francois Rossignol, M.D., Ph.D.
Address 0 0
Romark Laboratories L.C.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications